Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

FDA Approves TriClip TEER Device for Tricuspid Repair

L.A. McKeown

April 02, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

L.A. McKeown

December 21, 2021

News Daily News

FDA Approves Dabigatran for VTE in Children

Shelley Wood

June 22, 2021

News Daily News

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Michael O'Riordan

June 17, 2021

News Daily News

FDA Approves Rilonacept to Treat Recurrent Pericarditis and to Curb Recurrences

Shelley Wood

March 25, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Yael L. Maxwell

May 16, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

Advertisement

January 2026 Dispatch for the CV Team

FDA Approves TriClip TEER Device for Tricuspid Repair

FDA Grants MACE Reduction Indication for Semaglutide

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

FDA Approves Two Additional Indications for Rivaroxaban in Children

FDA Approves Dabigatran for VTE in Children

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

FDA Approves Rilonacept to Treat Recurrent Pericarditis and to Curb Recurrences

FDA Approves Evinacumab for Rare Homozygous FH

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content